Healthcare • Biotechnology
EODHD (TTM) · as of Oct 13, 2026
End-of-day close from stored market data, not a live quote.
Sign in to see your position size
We’ll show you if OBIO is in your portfolio and how much it contributes.
Sign inLoading market dates
No upcoming ex-dividend date announced
No 8-K filings in the last 30 days.
16 top institutions tracked
Last 13F trend: accumulating (light)
Unlock crowding heatmapUnlock filer discoverySentiment: neutral
Last trade: sell 13 days ago
Red flags: 1
77 filers reported a long position in OBIO for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
| Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|
| RTW INVESTMENTS, LP | $41.2M | 9.6M | +15% |
| PERCEPTIVE ADVISORS LLC | $21.7M | 5M | Unchanged |
| BlackRock, Inc. | $10.8M | 2.5M | +294.9% |
| VANGUARD CAPITAL MANAGEMENT LLC | $8.7M | 2M | -8.2% |
| GEODE CAPITAL MANAGEMENT, LLC | $4.4M | 1M | +107.6% |
| Alyeska Investment Group, L.P. | $4.3M | 1M | Unchanged |
| Propel Bio Management, LLC | $3.9M | 896.7K | Unchanged |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AME | $2.8M | 642.2K | New |
| STATE STREET CORP | $2.2M | 516.1K | +204.6% |
| RICE HALL JAMES & ASSOCIATES, LLC | $1.8M | 424K | +2,131.5% |
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.